一分钟看懂
这是一项关于结直肠癌的II 期 / III 期研究，登记的药物或干预包括Node-Sparing Radiotherapy plus Chemotherapy and PD-1 inhibitor；Conventional Radiotherapy plus Chemotherapy，当前状态为招募中。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Node-Sparing Radiotherapy plus Chemotherapy and PD-1 inhibitor；Conventional Radiotherapy plus Chemotherapy · II 期 / III 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁至75 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The Sixth Affiliated Hospital of Sun Yat-sen University · 广州
公开的入选条件
- * • Voluntarily signs a written informed consent form.
- Aged between 18 and 75 years at the time of enrollment.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Expected survival of more than 2 years.
- Histologically confirmed rectal adenocarcinoma.
- Tumor biopsy indicates proficient mismatch repair (pMMR), defined by positive immunohistochemical staining for MLH1, MSH2, MSH6, and PMS2, or molecular testing confirms microsatellite stability (MSS).
- Clinical stage T3-4N0M0 or TanyN+M0 based on the 8th edition of the AJCC TNM classification, as evaluated by high-resolution MRI ± endoscopic ultrasound/transrectal ultrasonography, with the tumor located in the mid-to-lower rectum below the peritoneal reflect
- Prior to enrollment, a qualified surgical attending physician must assess the patient's medical history and confirm eligibility for curative R0 resection.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06958432；登记信息更新于 2026-09-28。